HanchorBio
- Company typePublic
- Founded2020
- HeadquartersTaipei, Taiwan
- Headcount51–100
- GTM typeB2B
- OfferingServices
HanchorBio firmographics
Firmographics- Name
- HanchorBio
- Legal name
- HanchorBio Inc.
- Website
- https://hanchorbio.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Ipo
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
HanchorBio industry classification
Industry- Product category
- Immuno-Oncology Biologics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Fusion Proteins & Fc-Engineered Biologics (HLAAAAAD)
- akta.pro secondary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where HanchorBio is headquartered
LocationHeadquarters
- HQ city
- Taipei
- HQ country
- Taiwan
- HQ region
- Asia
Offices3 records
Markets served
HanchorBio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Licensing and Milestone Payments: HanchorBio generates revenue through out-licensing of its clinical-stage drug candidates to global pharmaceutical partners. The company received an upfront payment from the HCB101 licensing agreement with Henlius valued at up to US$202 million (including upfront, development, regulatory, and commercial milestones). The company reported 2025 revenue of NT$312 million from this first licensing deal, representing its first licensing revenue. Future revenue is expected to come from additional licensing deals, milestone payments, and royalty streams as programs advance through clinical development and commercialization.
- Government Grants and Subsidies: The company receives support from government programs for R&D activities, including Taiwan's biotechnology development incentives. 2024 R&D investment totaled NT$789 million.
- IPO Proceeds and Capital Markets: HanchorBio completed its IPO on the Taiwan Innovation Board in May 2026, raising NT$680 million in a pre-listing capital increase in September 2025, with the IPO issuing 9.4 million new shares at NT$120 per share. Post-IPO, the company holds approximately US$140 million in cash and available bank credit facilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | No commercialized products; company in clinical development stage |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
HanchorBio product offering
Product offeringCore offering
HanchorBio is a clinical-stage biopharmaceutical company developing next-generation multi-functional fusion protein immunotherapies using its proprietary FBDB™ (Fc-Based Designer Biologics) platform. The company advances a pipeline of clinical and preclinical candidates — including the CD47-SIRPα inhibitor HCB101 and the tri-specific HCB301 — targeting oncology and autoimmune diseases, and generates revenue primarily by out-licensing clinical-stage assets and milestones to global pharmaceutical partners.
Differentiator
Problem solved
Functional benefit
Products and services
- HCB101 — SIRPα–IgG4 Fc Fusion Protein (CD47-SIRPα inhibitor) Investigational biologic designed via AlphaFold-guided structural modeling to block the CD47-SIRPα innate immune checkpoint while minimizing red blood cell binding, delivering a cytopenia-sparing safety profile and >99% CD47 receptor occupancy at therapeutic doses. Developed for advanced solid tumors (gastric, head and neck, colorectal, triple-negative breast cancer) as a combination backbone; licensed to Henlius for mainland China and certain territories.
- HCB301 — Tri-specific SIRPα–PD-L1–TGF-β Fusion Protein First-in-class investigational tri-specific fusion protein designed to simultaneously modulate the CD47/SIRPα, PD-L1/PD-1, and TGF-β/TGFβ-R pathways within a single molecule for immune-resistant solid tumors.
- HCB206 — Dual-Target SIRPα–CD20 Fusion Protein Investigational dual-target fusion protein combining targeted B-cell depletion with engineered innate immune (CD47-SIRPα) mechanism, designed to minimize hematologic effects; preclinical data show approximately 6-fold greater clearance of pathogenic B cells vs. competitors while remaining minimally active in healthy cells. Developed for B-cell-driven autoimmune diseases (e.g., SLE) and oncology.
- FBDB™ Platform — Fc-Based Designer Biologics Proprietary modular Fc-based scaffold engineering platform integrating AI-guided structural design (AlphaFold) for rational engineering of multi-functional fusion proteins targeting innate and adaptive immune pathways. Licensed to enable differentiated antibody therapeutics in oncology and autoimmune diseases.
Quantifiable outcome
- 80% objective response rate (ORR) in Phase 2a mid-dose cohort for second-line gastric cancer (HCB101 + ramucirumab + paclitaxel), vs. 26.5% historical ORR for standard-of-care ramucirumab + paclitaxel alone
- +7 more outcomes
Companies that use HanchorBio
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
HanchorBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature6 records
HanchorBio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor and core.
- Institute of Tsinghua University, HebeiminorHanchorBio launched a research collaboration with the Institute of Tsinghua University, Hebei, to characterize the antitumor mechanisms and translational biology of HCB101. The collaboration focuses on in vivo studies spanning tumor immunity, immune cell function, antigen presentation, macrophage-mediated phagocytosis, downstream immune signaling, and hematologic biology, strengthening the scientific foundation for HCB101 development.
- National Yang Ming Chiao Tung University (NYCU)minorHanchorBio entered a research collaboration with NYCU's College of Engineering Bioscience to advance AI-enabled biologics discovery. The collaboration integrates generative AI with experimental validation to improve speed and efficiency of early-stage candidate design and evaluation. NYCU's Drug Design and Systems Biology Laboratory (led by Prof. Jinn-Moon Yang) contributes AI model development, sequence prediction, and computational analysis capabilities, combined with HanchorBio's biologics engineering and translational validation.
- Bloomberg (Bloomberg Intelligence)minorHanchorBio selected Bloomberg's data and research content, including Bloomberg Intelligence's Disease dashboard, to support strategic decision-making across portfolio planning, pipeline development, competitive monitoring, business development, and capital markets activities. The partnership extends the company's intelligence-driven approach from molecule design to broader portfolio and market strategy.
- WuXi BiologicscoreHanchorBio entered a strategic partnership with WuXi Biologics (2269.HK), a leading global CRDMO, for end-to-end biologics development and manufacturing services. WuXi Biologics provides integrated services including cell line development, process development, bioassay development, drug product formulation, and GMP manufacturing for HanchorBio's next-generation bi- and multi-functional fusion protein programs. The partnership leverages WuXi Biologics' established capabilities in complex biologics (supporting 945 integrated platform projects as of 2025) to accelerate clinical translation, enhance CMC execution efficiency, and support scalable global development of HanchorBio's FBDB™ platform-derived immunotherapy portfolio.
Scale indicators12 records
Recent moves10 records
Expansion highlights5 records
HanchorBio competitors and assessment
Company assessmentEmerging players
- Cullinan Oncology: Clinical-stage IO company with multiple modality programs including bispecifics. Comparable clinical-stage IO portfolio strategy with licensing optionality for individual programs.
- Werewolf Therapeutics: Clinical-stage biotech developing conditionally-activated multi-specific IO biologics (PREDATOR platform). Comparable engineered multi-functional biologic platform for oncology, though smaller and INDUCER-conditioned.
Direct peers
- ALX Oncology Holdings: Clinical-stage biotech developing CD47/SIRPα pathway inhibitors (e.g., evorpacept). Most direct competitor to HCB101 with overlapping mechanism and oncology indications; comparable clinical-stage positioning and licensing-focused BD strategy.
- Arch Oncology: Private clinical-stage biotech developing anti-CD47 antibodies for oncology. Directly comparable CD47-targeting mechanism and hematologic-toxicity differentiation strategy.
- Trillium Therapeutics: Pioneer in CD47/SIRPα therapeutics (TTI-621, TTI-622), acquired by Pfizer in 2021 for ~US$2.2B. Closest historical comparable for HanchorBio's CD47 strategy and validates Big Pharma appetite for the target.
- Akeso, Inc. China-based biotech commercializing bispecific antibodies (e.g., ivonescimab PD-1/VEGF). Closest Asian comparable on multi-functional biologics design and licensing-driven growth model.
- RemeGen Co., Ltd. Chinese biotech commercializing novel antibody therapeutics including fusion proteins (telitacicept, a TACI-Fc fusion). Directly comparable on Asia-originated fusion protein platform and licensing partnerships.
- Compass Therapeutics: Clinical-stage IO biotech developing bispecific antibodies (e.g., CTX-009 DR5/VEGF). Comparable multi-specific antibody platform with oncology focus and similar clinical-stage positioning.
Broad incumbents
- Innovent Biologics: Established Chinese biologics company with commercial PD-1 (sintilimab) and broad IO pipeline. Comparable Asian biologics developer at scale, although far broader and later-stage than HanchorBio.
- Sino Biopharmaceutical Limited: Major Chinese pharmaceutical conglomerate and existing HanchorBio Series A lead investor. Comparable Asian pharma exposure and potential downstream partner, though vastly larger and more diversified.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
HanchorBio social profiles
Digital presenceHanchorBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
HanchorBio leadership team
Management profileNumber of profiles
Profiles11 records
HanchorBio subsidiaries and ownership
Company hierarchySubsidiaries3 records
HanchorBio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HanchorBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HanchorBio
What does HanchorBio do?
HanchorBio is a clinical-stage biopharmaceutical company developing next-generation multi-functional fusion protein immunotherapies using its proprietary FBDB™ (Fc-Based Designer Biologics) platform. The company advances a pipeline of clinical and preclinical candidates — including the CD47-SIRPα inhibitor HCB101 and the tri-specific HCB301 — targeting oncology and autoimmune diseases, and generates revenue primarily by out-licensing clinical-stage assets and milestones to global pharmaceutical partners.
Is HanchorBio a public or private company?
HanchorBio is a public company. It is currently ipo.
When was HanchorBio founded?
HanchorBio was founded in 2020. It employs 51 to 100 people.
Where is HanchorBio based?
HanchorBio is headquartered in Taipei, Taiwan, in the Asia region.
How does HanchorBio make money?
Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are government Grants and Subsidies and IPO Proceeds and Capital Markets.
Who are HanchorBio's main competitors?
Emerging players on record are Cullinan Oncology and Werewolf Therapeutics. Direct peers are ALX Oncology Holdings, Arch Oncology, Trillium Therapeutics, Akeso, Inc., RemeGen Co., Ltd. and Compass Therapeutics. Broad incumbents are Innovent Biologics and Sino Biopharmaceutical Limited.
Does HanchorBio have an API?
No public API is recorded for HanchorBio.
What industry is HanchorBio in?
HanchorBio's product category is Immuno-Oncology Biologics. Its primary akta.pro industry code is HLAAAAAD, Fusion Proteins & Fc-Engineered Biologics, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.